Inflammatory Mechanisms in Atherosclerosis, Glaxo-Wellcome Medicines Research Centre, Stevenage, Herts, UK, 3rd July 1995

Author： Black D.   Reilly C. F.  

Publisher： Springer Publishing Company

ISSN： 1023-3830

Source： Inflammation Research, Vol.46, Iss.7, 1997-07, pp. : 237-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Paediatric Medicines Research in the UK: How to Move Forward?

By Wong I.   Sweis D.  

Drug Safety, Vol. 26, Iss. 8, 2003-01 ,pp. : 529-537

Adis International

Access to resources Recommend Favorite

Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 10, 2012-05 ,pp. : 1132-1148

Bentham Science Publishers

Access to resources Recommend Favorite

The antiviral valaciclovir [`Valtrex'; Glaxo Wellcome] has been launched in Japan

By  

Inpharma, Vol. 1, Iss. 1260, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

APPLICATIONS OF PHARMACOGENETICS TO DRUG DEVELOPMENT: THE GLAXO WELLCOME EXPERIENCE1 *

By ARLEDGE TERESA   FREEMAN ANDREW   ARBUCKLE JULIAN   MOSTELLER MICHAEL   MANASCO PENELOPE  

Drug Metabolism Reviews, Vol. 32, Iss. 3-4, 2000-10 ,pp. : 387-394

Informa Healthcare

Access to resources Recommend Favorite

Glaxo Wellcome: top of the class for small molecules; where in genomics?

By Thomas S.   Burke J.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 2, 1998-02 ,pp. : 103-109

Informa Healthcare

Access to resources Recommend Favorite